Acrivon Therapeutics, Inc. (ACRV) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 11.45M USD | Liabilities, Current |
| Cash and equivalents | 41.42M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.45M | $41.42M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $11.05M | $34.06M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $15.66M | $41.50M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $14.89M | $35.41M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $13.43M | $41.90M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $13.55M | $39.15M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $17.21M | $39.82M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $14.82M | $43.41M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $11.28M | $46.01M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $9.04M | $24.61M | $85.37M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $13.30M | $36.02M | $91.44M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $9.30M | $29.86M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $7.02M | $38.07M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $5.68M | $27.49M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.52M | $29.52M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.39M | $32.08M | $44.74M | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $83.86M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $90.77M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $2.91M | $99.60M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $3.61M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |